---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-102700"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T12:55:53.452746+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics FY2025 revenue up 10% to $116.6M; net income down; guides FY2026 lower

## Summary
- Full-year 2025 revenue $116.6M (+10.2% YoY); net income $9.9M vs $17.9M; non-GAAP adj. net income $18.9M vs $16.9M.
- Q4 2025 revenue $37.2M (+33.3% YoY); net loss $1.4M vs income $0.6M; non-GAAP adj. net income $4.3M vs $1.1M.
- FY2026 revenue guidance $100.5M–$111.0M, a decline of 4.8%–13.8% vs 2025, citing regulatory priorities and market dynamics.
- Agreed to acquire Cullgen in ~$300M all-stock deal; transaction expected to close Q2 2026, adding protein degrader platform.
- Hydronidone NDA for conditional approval in China (CHB fibrosis) planned H1 2026; U.S. IND for MASH fibrosis targeted in 2026.

## SEC filing metadata
- accession: 0001193125-26-102700
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000119312526102700/0001193125-26-102700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000119312526102700/gyre-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-102700
- JSON: https://secwatch.observer/filing/0001193125-26-102700.json
- Plain text: https://secwatch.observer/filing/0001193125-26-102700.txt

## Key facts
- Earnings Releases
  GYRE THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2025 results: revenue $116.6 million. Guidance reaffirmed.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Revenue: $116.6 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000119312526102700/0001193125-26-102700-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.